Gynecologic cancers:

Indications for: ELAHERE

Folate receptor-alpha (FRα) positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, in adults who have received 1–3 prior systemic treatment regimens.

Adult Dosage:

Select patients based on the presence of FRα tumor expression. Premedicate with a corticosteroid (IV), antihistamine, antipyretic, and antiemetic, and with ophthalmic topical steroids, lubricating eye drops; see full labeling. Administer as an IV infusion 6mg/kg adjusted ideal body weight (AIBW) once every 3 weeks (21-day cycle), until disease progression or unacceptable toxicity. Infuse initially at a rate of 1mg/min; may increase to 3mg/min if well tolerated after 30mins, then to 5mg/min after next 30mins (max rate). Dose modifications and reductions: see full labeling. 

Children Dosage:

Not established.

Boxed Warning:

Ocular toxicity.

ELAHERE Warnings/Precautions:

Monitor for ocular toxicity; withhold, reduce, or permanently discontinue based on severity of reactions. Conduct eye exam including visual acuity and slit lamp exam prior to initiation, every other cycle for the first 8 cycles, and as clinically indicated. Advise to avoid contact lenses during treatment. Monitor for pneumonitis; withhold and consider reducing dose if persistent or recurrent Grade 2 pneumonitis develop; permanently discontinue if Grade 3/4 penumonitis occurs. Monitor for neuropathy; if new or worsening peripheral neuropathy occurs, withhold, reduce dose, or permanently discontinue based on severity of reactions. Moderate to severe hepatic impairment: not recommended. Embryo-fetal toxicity. Advise females of reproductive potential to use effective contraception during and for 7 months after the last dose. Pregnancy: exclude status prior to initiation. Nursing mothers: not recommended (during and for 1 month after the last dose). 

ELAHERE Classification:

Folate receptor alpha-directed antibody-drug conjugate.

ELAHERE Interactions:

May be potentiated by strong CYP3A4 inhibitors; monitor. 

Adverse Reactions:

Vision impairment, fatigue, nausea, keratopathy, abdominal pain, peripheral neuropathy, diarrhea, constipation, dry eye, lab abnormalities (increased AST/ALT/ALP, decreased lymphocytes, decreased albumin, decreased magnesium, decreased leukocytes, decreased neutrophils, decreased hemoglobin); intestinal obstruction, ascites, infection, pleural effusion, pneumonitis, infusion-related reactions, hypersensitivity, others.


Hepatic. >99% serum protein bound. 

Drug Elimination:

Renal. Half-life: 4.8 days.

Generic Drug Availability:


How Supplied:

Single-dose vial (20mL)—1